These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Development and Stability Study of an Omeprazole Suppository for Infants. Bestebreurtje P; Roeleveld N; Knibbe CAJ; van Sorge AA; Plötz FB; de Wildt SN Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):627-633. PubMed ID: 32594306 [TBL] [Abstract][Full Text] [Related]
4. To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid. Chuong MC; Taglieri CA; Kerr SG Int J Pharm Compd; 2017; 21(6):500-512. PubMed ID: 29220339 [TBL] [Abstract][Full Text] [Related]
5. Stability of omeprazole in an extemporaneously prepared oral liquid. Quercia RA; Fan C; Liu X; Chow MS Am J Health Syst Pharm; 1997 Aug; 54(16):1833-6. PubMed ID: 9269520 [TBL] [Abstract][Full Text] [Related]
6. Stability of Diazepam Enema Extemporaneous Formulation in Manzoni Base. Lopalco A; Lopedota A; Aurelio F; Forgia F; Fontana S; Franco M; Denora N Int J Pharm Compd; 2021; 25(5):427-430. PubMed ID: 34623969 [TBL] [Abstract][Full Text] [Related]
7. The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment. Meissner S; Bansal M; Dela CPD; Hanning S; Svirskis D Int J Pharm Compd; 2020; 24(2):140-147. PubMed ID: 32196476 [TBL] [Abstract][Full Text] [Related]
8. Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion. Kambia NK; Luyckx M; Dine T; Dupin-Spriet T; Gressier B; Brunet C J Clin Pharm Ther; 2009 Feb; 34(1):25-31. PubMed ID: 19125900 [TBL] [Abstract][Full Text] [Related]
9. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation. Pabari RM; McDermott C; Barlow J; Ramtoola Z Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007 [TBL] [Abstract][Full Text] [Related]
10. Influence of sulfobutylether-beta-cyclodextrin on the stability of S- and R- omeprazole. Agatonovic-Kustrin S; Williams D; Ibrahim N; Glass BD Curr Drug Discov Technol; 2007 Oct; 4(3):192-7. PubMed ID: 17986001 [TBL] [Abstract][Full Text] [Related]
11. Stability of partial doses of omeprazole-sodium bicarbonate oral suspension. Johnson CE; Cober MP; Ludwig JL Ann Pharmacother; 2007 Dec; 41(12):1954-61. PubMed ID: 17956960 [TBL] [Abstract][Full Text] [Related]
12. Stability of omeprazole in SyrSpend SF Alka (reconstituted). Whaley PA; Voudrie MA; Sorenson B Int J Pharm Compd; 2012; 16(2):164-6. PubMed ID: 23050328 [TBL] [Abstract][Full Text] [Related]
13. Development of an omeprazole parenteral formulation with hydroxypropyl-beta-cyclodextrin. Holvoet C; Heyden YV; Plaizier-Vercammen J Pharm Dev Technol; 2007; 12(3):327-36. PubMed ID: 17613896 [TBL] [Abstract][Full Text] [Related]
14. Solid self-nanoemulsifying drug delivery system filled in enteric coated hard gelatin capsules for enhancing solubility and stability of omeprazole hydrochloride. Al-Nimry SS; Alkhamis KA; Altaani BM Pharm Dev Technol; 2020 Jun; 25(5):588-600. PubMed ID: 31976799 [TBL] [Abstract][Full Text] [Related]
15. Study of comparative bioavailability of omeprazole pellets. Karim S; Hay YK; Baie SH; Bukhari NI; Murtaza G Acta Pol Pharm; 2014; 71(3):463-8. PubMed ID: 25265826 [TBL] [Abstract][Full Text] [Related]
16. Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base. Spennacchio A; Lopedota A; la Forgia F; Fontana S; Franco M; Denora N Int J Pharm Compd; 2023; 27(1):72-77. PubMed ID: 36720064 [TBL] [Abstract][Full Text] [Related]
17. Quality evaluation of extemporaneous delayed-release liquid formulations of lansoprazole. Melkoumov A; Soukrati A; Elkin I; Forest JM; Hildgen P; Leclair G Am J Health Syst Pharm; 2011 Nov; 68(21):2069-74. PubMed ID: 22011986 [TBL] [Abstract][Full Text] [Related]
18. [Visual documentation of the stability of intravenous solutions of omeprazole (Losec) and pantoprazole (Pantoloc)]. Leitner A; Zöllner P Wien Med Wochenschr; 2002; 152(21-22):568-73. PubMed ID: 12506681 [TBL] [Abstract][Full Text] [Related]
19. Formulation and Stability Study of Omeprazole Oral Liquid Suspension for Pediatric Patients. Boscolo O; Perra F; Salvo L; Buontempo F; Lucangioli S Hosp Pharm; 2020 Oct; 55(5):314-322. PubMed ID: 32999501 [No Abstract] [Full Text] [Related]
20. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Möschwitzer J; Achleitner G; Pomper H; Müller RH Eur J Pharm Biopharm; 2004 Nov; 58(3):615-9. PubMed ID: 15451536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]